Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

TECX

Tectonic Therapeutic Inc

Feb 13 • 04:00PM ET

22.28

-0.43 -1.89 %

Healthcare • Biotechnology • USA • NASD

Feb 10, 4:30 AMAstraZeneca's discontinuation of relaxin mimetic AZD3427 trial due to efficacy concerns sparked premarket plunge.

Peers: VRTX REGN AMGN GILD BIIB BMRN INCY EXEL NBIX RGEN

| Held by: VTI IWM VXF IBB IWN VTWO IWC SBIO IWO BBC

Index	RUT	P/E	-	EPS (ttm)	-3.85	Insider Own	43.25%	Shs Outstand	18.71M	Perf Week	-8.58%
Market Cap	417.00M	Forward P/E	-	EPS next Y	-4.83	Insider Trans	0.11%	Shs Float	10.62M	Perf Month	13.27%
Enterprise Value	149.22M	PEG	-	EPS next Q	-1.11	Inst Own	63.60%	Short Float	35.49%	Perf Quarter	18.13%
Income	-67.30M	P/S	-	EPS this Y	38.74%	Inst Trans	2.64%	Short Ratio	9.83	Perf Half Y	-8.95%
Sales	0.00M	P/B	1.56	EPS next Y	-15.50%	ROA	-30.20%	Short Interest	3.77M	Perf YTD	6.81%
Book/sh	14.30	P/C	1.55	EPS next 5Y	6.98%	ROE	-32.21%	52W High	36.11 -38.30%	Perf Year	-35.27%
Cash/sh	14.37	P/FCF	-	EPS past 3/5Y	41.06% 26.54%	ROIC	-25.15%	52W Low	13.70 62.63%	Perf 3Y	11.85%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	15.39% 10.47%	Perf 5Y	-88.49%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	60.41%	Oper. Margin	-	ATR (14)	2.35	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	29.15	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	53.66	Recom	1.11
Dividend Gr. 3/5Y	- -	Current Ratio	29.15	EPS Q/Q	15.44%	SMA20	4.88%	Beta	1.58	Target Price	79.38
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	8.21%	Rel Volume	1.07	Prev Close	22.71
Employees	51	LT Debt/Eq	0.00	Earnings	Nov 06 AMC	SMA200	10.37%	Avg Volume	383.58K	Price	22.28
IPO	Jun 21, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.39% -	Trades		Volume	411,173	Change	-1.89%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-25	Initiated	Wells Fargo	Overweight	$101
Sep-03-25	Initiated	Oppenheimer	Outperform	$80
Jul-21-25	Initiated	Truist	Buy	$64
Jun-11-25	Resumed	Raymond James	Outperform	$76
Apr-21-25	Initiated	Mizuho	Outperform	$51
Nov-20-24	Initiated	Raymond James	Outperform	$65
Aug-22-24	Initiated	Wells Fargo	Overweight	$55
Jun-26-24	Initiated	Piper Sandler	Overweight
Jun-24-24	Initiated	TD Cowen	Buy
Dec-18-23	Downgrade	Mizuho	Buy → Neutral
Jan-05-22	Downgrade	BTIG Research	Buy → Neutral
Nov-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$24 → $7
Jun-15-21	Initiated	BTIG Research	Buy	$23
May-27-21	Initiated	Needham	Buy	$28
Mar-09-21	Initiated	Barclays	Overweight	$23
Mar-02-21	Initiated	Stifel	Hold	$14
Nov-11-20	Initiated	Berenberg	Buy
Mar-31-20	Downgrade	H.C. Wainwright	Buy → Neutral	$13
Jun-27-19	Initiated	Mizuho	Buy	$28
Apr-05-19	Initiated	Janney	Buy

Show Previous Ratings

Feb-11-26 04:01PM	Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026 (GlobeNewswire)
Dec-10-25 02:13PM	Tectonic Therapeutic (TECX): LifeSci Capital Reiterates Buy Rating (Insider Monkey)
Dec-01-25 08:00AM	Tectonic Therapeutic to Participate in December Investor Conferences (GlobeNewswire)
Nov-06-25 04:01PM	Tectonic Therapeutic Announces Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +15.51%
Oct-29-25 04:01PM	Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF (GlobeNewswire) -5.48%
09:00AM	Loading…
Aug-28-25 09:00AM	Tectonic Therapeutic to Participate in September Investor Conferences (GlobeNewswire)
Aug-07-25 04:01PM	Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) -5.35%
Jun-30-25 08:00AM	Tectonic Therapeutic Joins Russell 3000 Index (GlobeNewswire)
Jun-24-25 05:42PM	Raymond James Resumes Coverage of Tectonic Therapeutic (TECX) With an Outperform Rating (Insider Monkey) +7.57%
May-17-25 10:40AM	Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025 (GlobeNewswire)
May-13-25 09:55AM	Wall Street Analysts See a 258.52% Upside in Tectonic Therapeutic, Inc. (TECX): Can the Stock Really Move This High? (Zacks)
May-08-25 04:01PM	Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +10.81% -5.99%
May-07-25 08:00AM	Tectonic Therapeutic To Present on May 15th, 2025 at the Bank of America Securities Health Care Conference (GlobeNewswire)
May-01-25 05:59AM	TipRanks Perfect 10 Picks: 2 Top-Scoring Stocks Earning Wall Streets Seal of Approval (TipRanks) -5.75%
Apr-23-25 05:51AM	Tectonic Therapeutic: A Buy On Massive Opportunity Of TX45 In PH HFpEF (Seeking Alpha)
08:00AM	Loading…
Apr-15-25 08:00AM	Tectonic Therapeutic to Present Phase 1b Data for TX45 at European Society of Cardiology Heart Failure 2025 (GlobeNewswire)
Mar-20-25 04:01PM	Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-04-25 08:26PM	Is Tectonic Therapeutic, Inc. (TECX) Among Stocks With At Least $20 Million In Insider Spending Recently? (Insider Monkey)
Feb-20-25 08:00AM	Tectonic Therapeutic to Participate in March Investor Conferences (GlobeNewswire)
Feb-03-25 06:30AM	Tectonic Announces $185 Million Private Placement (GlobeNewswire) -6.52%
Jan-30-25 06:30AM	Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF (GlobeNewswire) +113.22%
Dec-03-24 04:01PM	Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024 (GlobeNewswire)
Nov-26-24 04:01PM	Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-12-24 11:01PM	Tectonic Therapeutic Inc. Reports Q3 2024 Results (TipRanks)
Nov-11-24 05:00AM	Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein (GlobeNewswire)
Nov-07-24 04:01PM	Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Oct-22-24 04:01PM	Tectonic Therapeutic to Present Phase 1a Data at AHA 2024 (GlobeNewswire)
Sep-19-24 04:01PM	Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45 (GlobeNewswire)
Aug-20-24 04:01PM	Tectonic Therapeutic to Participate in September Investor Conferences (GlobeNewswire)
Aug-14-24 04:01PM	Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) +5.23%
04:01PM	Loading…
Jul-30-24 04:01PM	Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45 (GlobeNewswire)
Jun-20-24 04:01PM	Tectonic Therapeutic Announces Closing of Merger with AVROBIO as well as Concurrent Private Placement of $130.7 Million (Business Wire)
09:47AM	PLTR Stock: Palantir Bags New Partnership With ARPA-H for AI/ML (InvestorPlace)
08:26AM	Why Is Avrobio (AVRO) Stock Moving Today? (InvestorPlace)
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
May-15-24 11:27AM	Avrobio Insider Bought Shares Worth $971,493, According to a Recent SEC Filing (MT Newswires) +6.20%
May-13-24 09:53AM	AVRO Stock Earnings: Avrobio Beats EPS for Q1 2024 (InvestorPlace) +9.76%
Feb-27-24 10:50AM	Kuehn Law Encourages CHRD, AVRO, KAMN, and CTLT Investors to Contact Law Firm (PR Newswire)
Feb-01-24 02:25PM	Kuehn Law Encourages ICVX, CSTR, AVRO, and CALB Investors to Contact Law Firm (PR Newswire)
Jan-31-24 10:40AM	SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates TAST, AVRO, CALB (GlobeNewswire) +9.57%
06:42AM	Avrobios road ends in reverse merger with Tim Springer-backed startup (BioPharma Dive)
Jan-30-24 02:52PM	Avrobio's corporate tremor attracts Tectonic for reverse merger (FierceBiotech.com) -16.06%
02:38PM	SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates AVRO, CALB, BCAL (PR Newswire)
08:00AM	AVROBIO and Tectonic Therapeutic Announce Merger (Business Wire)
Nov-08-23 09:40AM	Is AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-23-23 09:40AM	Is AVROBIO (AVRO) Outperforming Other Medical Stocks This Year? (Zacks)
Oct-06-23 09:40AM	Has AVROBIO (AVRO) Outpaced Other Medical Stocks This Year? (Zacks)
Jul-13-23 07:08AM	AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46% (Zacks)
Jul-12-23 07:00AM	AVROBIO to Explore Strategic Alternatives (Business Wire) +45.96%
Jun-12-23 07:00AM	AVROBIO Completes Sale of Cystinosis Gene Therapy Program for $87.5 Million (Business Wire)
May-22-23 07:00AM	AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million (Business Wire) +69.01%
May-18-23 02:53PM	Avrobio Touts Positive Data Gene Therapy Trial For Cystinosis, Showing Treatment Durability Of Up To 36 Months (Benzinga) +45.33%
07:00AM	AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual Meeting (Business Wire)
May-11-23 07:00AM	AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update (Business Wire)
May-01-23 07:30AM	AVROBIO Announces Leadership Transition (Business Wire) -15.99%
Mar-23-23 07:00AM	AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update (Business Wire) -27.64%
Mar-03-23 07:00AM	AVROBIO to Participate in Cowens 43rd Annual Health Care Conference (Business Wire)
Feb-09-23 07:00AM	AVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposium 2023 (Business Wire) +7.69%
Jan-05-23 07:00AM	AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-07-22 07:30AM	AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy (Business Wire) -6.96%
Nov-17-22 07:00AM	AVROBIO to Share Comprehensive Gaucher Disease Program Update (Business Wire) +5.40%
Nov-08-22 07:00AM	AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Nov-07-22 07:00AM	AVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy Summit (Business Wire)
Nov-03-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-27-22 07:00AM	AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for First-in-Class Gene Therapy for Gaucher Disease (Business Wire)
Oct-25-22 07:00AM	AVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis (Business Wire)
Oct-18-22 07:00AM	AVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease (Business Wire) +12.37%
Oct-11-22 07:00AM	AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development (Business Wire)
Oct-06-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-27-22 07:00AM	AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress (Business Wire) -10.23%
Sep-20-22 07:00AM	AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis (Business Wire)
Sep-14-22 07:28AM	AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial (Business Wire)
Sep-08-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-31-22 07:00AM	AVROBIO to Participate in Four Upcoming Investor Conferences in September (Business Wire)
Aug-09-22 07:00AM	AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Aug-04-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-01-22 07:00AM	AVROBIO to Participate in Two Upcoming Investor Conferences in August (Business Wire)
Jul-13-22 07:00AM	AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome (Business Wire)
Jul-06-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.47%
May-18-22 03:12PM	AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study (Zacks) -8.57%
12:41PM	Avrobio's Pompe Disease Gene Therapy Shows Efficacy, Safety In Preclinical Study (Benzinga)
07:00AM	AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting (Business Wire)
May-17-22 12:15PM	AVROBIO Shares Jumps On Encouraging Data From Early-Stage Gene Therapy Study (Benzinga)
07:00AM	AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures (Business Wire)
May-16-22 07:00AM	AVROBIO to Present at the H.C. Wainwright Global Investment Conference (Business Wire)
May-10-22 07:00AM	AVROBIO Reports First Quarter 2022 Financial Results and Provides Business Update (Business Wire)
May-06-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-03-22 07:00AM	AVROBIO to Present New Clinical and Preclinical Data at the ASGCT 25th Annual Meeting (Business Wire)
Apr-06-22 12:36PM	bluebird (BLUE) Undertakes Restructuring Moves to Curb Cash Burn (Zacks)
07:00AM	AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-05-22 12:54PM	Corcept (CORT) Completes Enrolment in Mid-Stage Weight Gain Study (Zacks)
07:00AM	AVROBIO to Present at the 21st Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-17-22 07:00AM	AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update (Business Wire) +8.33%
Mar-01-22 07:00AM	AVROBIO to Present at Two Upcoming Investor Conferences in March (Business Wire)
Feb-21-22 12:14PM	2 Net Current Asset Value Stocks to Consider (GuruFocus.com)
Feb-09-22 12:55PM	After Fabry Trial Setback, Avrobio Hopes Rebound With Lysosomal Storage Disorder Data (Benzinga) -6.25%
07:00AM	AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis (Business Wire)
Feb-04-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-03-22 10:00AM	Here's Why AVROBIO, Inc. (AVRO) is Poised for a Turnaround After Losing 19.7% in 4 Weeks (Zacks)
Feb-01-22 07:00AM	AVROBIO Announces the Appointment of Sean OBryan as Chief Regulatory Officer (Business Wire)

Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCR). It develops a proprietary technology platform called GEODe to enable the discovery and development of GPCR-targeted biologic medicines. The company was founded by Timothy A. Springer and Andrew Kruse in November 2015 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
REICIN ALISE	Chief Executive Officer	Feb 11 '26	Buy	21.10	2,500	52,750	237,547	Feb 12 04:15 PM
Schwabish Marc	Chief Business Officer	Feb 10 '26	Option Exercise	2.38	4,500	10,710	25,814	Feb 12 04:15 PM
Lochner Daniel	Chief Financial Officer	Feb 10 '26	Buy	21.61	6,000	129,660	32,044	Feb 11 05:32 PM
REICIN ALISE	Chief Executive Officer	Dec 31 '25	Option Exercise	2.38	10,966	26,099	239,151	Jan 05 05:02 PM
McNamara Peter	Chief Scientific Officer	Dec 22 '25	Option Exercise	2.98	7,000	20,860	40,879	Dec 29 04:35 PM
SPRINGER TIMOTHY A	Director	Apr 11 '25	Buy	16.31	53,706	875,945	1,503,358	Apr 11 06:12 PM
SPRINGER TIMOTHY A	Director	Apr 10 '25	Buy	16.73	45,858	767,204	1,449,652	Apr 11 06:12 PM
SPRINGER TIMOTHY A	Director	Apr 09 '25	Buy	14.76	21,071	311,020	1,403,794	Apr 11 06:12 PM
SPRINGER TIMOTHY A	Director	Apr 11 '25	Buy	16.31	9,478	154,586	4,334,846	Apr 11 06:12 PM
SPRINGER TIMOTHY A	Director	Apr 10 '25	Buy	16.73	8,092	135,379	4,325,368	Apr 11 06:12 PM
SPRINGER TIMOTHY A	Director	Apr 09 '25	Buy	14.76	3,718	54,880	4,317,276	Apr 11 06:12 PM
SPRINGER TIMOTHY A	Director	Apr 07 '25	Buy	17.10	412,500	7,053,750	1,382,723	Apr 09 05:38 PM
SPRINGER TIMOTHY A	Director	Apr 07 '25	Buy	17.10	87,500	1,496,250	4,313,558	Apr 09 05:38 PM
MCGUIRE TERRANCE	Director	Apr 07 '25	Sale	17.10	500,000	8,550,000	573,062	Apr 07 05:02 PM

Open in Screener

IVVD

Invivyd Inc

Feb 13 • 04:00PM ET

1.56

+0.03 1.96 %

Healthcare • Biotechnology • USA • NASD

Peers: PFE MRNA BNTX MRK JNJ NVAX AZN-D GSK GILD SNY

| Held by: VTI XBI VXF ITOT PRFZ LABU BBC IBBQ BIB PWS

Index	-	P/E	-	EPS (ttm)	-0.47	Insider Own	18.47%	Shs Outstand	277.12M	Perf Week	-1.89%
Market Cap	432.31M	Forward P/E	-	EPS next Y	-0.23	Insider Trans	-0.44%	Shs Float	225.93M	Perf Month	-40.00%
Enterprise Value	350.02M	PEG	-	EPS next Q	-0.08	Inst Own	71.00%	Short Float	9.88%	Perf Quarter	-11.86%
Income	-59.86M	P/S	8.64	EPS this Y	72.67%	Inst Trans	26.34%	Short Ratio	3.32	Perf Half Y	95.17%
Sales	50.04M	P/B	3.59	EPS next Y	41.10%	ROA	-39.76%	Short Interest	22.33M	Perf YTD	-36.84%
Book/sh	0.43	P/C	5.09	EPS next 5Y	48.75%	ROE	-67.94%	52W High	3.07 -49.18%	Perf Year	13.04%
Cash/sh	0.31	P/FCF	-	EPS past 3/5Y	11.20% -24.99%	ROIC	-63.24%	52W Low	0.46 239.13%	Perf 3Y	-17.02%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	86.97%	Volatility	10.21% 8.66%	Perf 5Y	-
Dividend TTM	-	EV/Sales	6.99	EPS Y/Y TTM	75.73%	Oper. Margin	-124.37%	ATR (14)	0.17	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.46	Sales Y/Y TTM	332.71%	Profit Margin	-119.63%	RSI (14)	33.93	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	2.47	EPS Q/Q	87.90%	SMA20	-16.53%	Beta	0.64	Target Price	8.00
Payout	-	Debt/Eq	0.03	Sales Q/Q	41.17%	SMA50	-29.70%	Rel Volume	0.15	Prev Close	1.53
Employees	99	LT Debt/Eq	0.02	Earnings	Nov 06 BMO	SMA200	9.59%	Avg Volume	6.73M	Price	1.56
IPO	Aug 06, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	25.00% 0.24%	Trades		Volume	1,038,257	Change	1.96%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-22-25	Initiated	BTIG Research	Buy	$10
Nov-25-25	Downgrade	D. Boral Capital	Buy → Hold
Oct-06-25	Initiated	Cantor Fitzgerald	Overweight	$10
Apr-05-24	Upgrade	Guggenheim	Neutral → Buy	$9
Mar-26-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$4 → $10
Dec-19-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$1 → $4
May-01-23	Initiated	H.C. Wainwright	Buy	$5

Feb-03-26 07:01AM	Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration (GlobeNewswire) +8.05%
Jan-22-26 07:01AM	Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention (GlobeNewswire)
Jan-20-26 07:01AM	Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026 (GlobeNewswire) -8.57%
Jan-14-26 02:13PM	?Invivyd (IVVD) Reports Strong Q4 Growth, Advances COVID Antibody to Phase 3 (Insider Monkey) +11.11%
Jan-08-26 07:01AM	Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights (GlobeNewswire)
11:13AM	Loading…
Dec-31-25 11:13AM	BTIG Initiates Invivyd (IVVD) Coverage, Cites VYD2311's Superior Market Potential Over Pemgarda (Insider Monkey)
Dec-23-25 07:05AM	Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID (GlobeNewswire)
07:01AM	Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID (GlobeNewswire)
Dec-22-25 09:47AM	Arcellx initiated, Cummins upgraded: Wall Street's top analyst calls (The Fly) +25.22%
Dec-18-25 01:14AM	Invivyd, Inc. (IVVD): Advancing RSV Antibody VBY329 Amid Analyst Downgrade (Insider Monkey)
Nov-25-25 07:01AM	Invivyd to Participate at the 8th Annual Evercore Healthcare Conference (GlobeNewswire) -5.42%
Nov-24-25 07:01AM	Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness (GlobeNewswire)
Nov-17-25 10:40PM	Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +20.85% -10.92%
04:01PM	Invivyd Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Nov-06-25 09:15AM	Invivyd, Inc. (IVVD) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:01AM	Loading…
07:01AM	Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-05-25 07:52AM	Invivyd Inc (IVVD) Q3 2025 Earnings Report Preview: What to Expect (GuruFocus.com) +8.57%
07:40AM	Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-04-25 10:00AM	Viridian Therapeutics, Inc. (VRDN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks) -13.04%
Nov-03-25 04:01PM	Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025 (GlobeNewswire) -8.52%
Oct-28-25 07:01AM	Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID (GlobeNewswire)
Oct-06-25 07:01AM	Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID (GlobeNewswire) +22.41%
Sep-24-25 04:01PM	Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors (GlobeNewswire) +5.17% -6.56%
Sep-23-25 07:25PM	Invivyd, Inc. (IVVD) Secures FDA Path for COVID-19 Antibody Approval (Insider Monkey)
Sep-17-25 07:01AM	Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer (GlobeNewswire) -8.73%
Sep-04-25 07:01AM	SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025 (GlobeNewswire)
Aug-27-25 07:01AM	Invivyd to Participate in Upcoming Investor Conferences (GlobeNewswire) -15.44%
Aug-26-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +84.03%
Aug-22-25 12:00PM	Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares (GlobeNewswire)
Aug-20-25 11:58PM	Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +11.00% -16.71%
04:01PM	Loading…
04:01PM	Invivyd Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Aug-18-25 04:32PM	Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG ("Stratus") (GlobeNewswire) -17.82%
Aug-14-25 06:00PM	Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -11.54%
04:49PM	Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
04:47PM	Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19 (GlobeNewswire)
Aug-12-25 05:40PM	Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Aug-08-25 05:30AM	The Race to Find a Measles Treatment as Infections Surge (The Wall Street Journal) +5.88%
Aug-07-25 06:15PM	Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +5.10%
Aug-06-25 08:20AM	Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates (Zacks)
Jul-23-25 07:01AM	Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome (GlobeNewswire) +5.26%
Jul-21-25 07:05AM	National Comprehensive Cancer Network (NCCN) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population (GlobeNewswire)
Jul-02-25 07:01AM	Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome (GlobeNewswire)
Jun-26-25 07:01AM	Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection (GlobeNewswire) +13.43%
Jun-02-25 03:49AM	COVIDs remaining biotech contenders navigate a dwindling market (Pharma Voice)
May-29-25 02:36PM	H.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue Shortfall (Insider Monkey)
May-27-25 07:01AM	Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus (GlobeNewswire) +20.15%
May-23-25 07:01AM	Invivyd Announces Inclusion of PEMGARDA (pemivibart) in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas (GlobeNewswire)
May-21-25 09:30AM	Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19 (GlobeNewswire) -5.52%
May-16-25 03:08AM	Invivyd Inc (IVVD) Q1 2025 Earnings Call Highlights: Strategic Shifts and Financial Discipline ... (GuruFocus.com) +10.33%
01:57AM	Q1 2025 Invivyd Inc Earnings Call (Thomson Reuters StreetEvents)
May-15-25 08:15AM	Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -15.78%
07:01AM	Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
May-14-25 09:53AM	What To Expect From Invivyd Inc (IVVD) Q1 2025 Earnings (GuruFocus.com)
07:01AM	Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy (GlobeNewswire)
May-13-25 07:01AM	Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference (GlobeNewswire)
May-12-25 07:01AM	Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles (GlobeNewswire) +29.67%
May-08-25 07:01AM	Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025 (GlobeNewswire)
Apr-21-25 09:58AM	What's Going On With Invivyd Stock On Monday? (Benzinga) +10.00%
07:01AM	Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank (GlobeNewswire)
Mar-26-25 04:15PM	Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors (GlobeNewswire) -6.70%
Mar-20-25 09:25AM	Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:01AM	Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Mar-12-25 09:40AM	Are Investors Undervaluing Invivyd, Inc. (IVVD) Right Now? (Zacks)
Mar-05-25 07:05AM	Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1 (GlobeNewswire)
Mar-02-25 11:32AM	Why Invivyd, Inc. (IVVD) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-28-25 12:12PM	Adagio Medical cuts workforce and pauses cryo catheter launch in EU (Medical Device Network) -6.45%
Feb-24-25 07:05AM	FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients (GlobeNewswire) -29.94%
Feb-18-25 10:27AM	Why Invivyd, Inc. (IVVD) Is Soaring This Year So Far (Insider Monkey) -9.32%
Feb-10-25 07:00AM	Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 (GlobeNewswire) -23.04%
Feb-05-25 09:30AM	Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold (GlobeNewswire) +68.80%
Feb-03-25 07:20PM	Why Invivyd Inc (IVVD) Is Skyrocketing So Far In 2025 (Insider Monkey) +196.34% +17.92%
07:00AM	Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population (GlobeNewswire)
06:55AM	Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability (GlobeNewswire)
Jan-27-25 07:01AM	Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA's Gating Request for Completing Its Review of EUA Request for PEMGARDA (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients (GlobeNewswire) -12.85%
Jan-10-25 12:12PM	What's Going On With COVID-19 Antibody Developer Invivyd Stock On Friday? (Benzinga)
07:01AM	Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Dominant SARS-CoV-2 Variant XEC (GlobeNewswire)
Jan-07-25 09:34AM	Why Invivyd, Inc. (IVVD) Is Among the Best Penny Stocks to Invest In According to Media? (Insider Monkey)
Dec-17-24 06:25AM	Adagio Medical announces Todd Usen as new CEO and director (Medical Device Network) +8.77%
Nov-15-24 03:17AM	Q3 2024 Invivyd Inc Earnings Call (Thomson Reuters StreetEvents)
02:11AM	Invivyd Inc (IVVD) Q3 2024 Earnings Call Highlights: Strong Revenue and Strategic Growth Amidst ... (GuruFocus.com)
Nov-14-24 08:20AM	Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -11.18%
07:05AM	Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
07:01AM	Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor (GlobeNewswire)
Nov-13-24 07:27AM	Invivyd Inc (IVVD) Q3 2024 Earnings Report Preview: What to Expect (GuruFocus.com) -11.00%
Nov-12-24 08:30AM	Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively (GlobeNewswire)
Nov-06-24 08:01AM	Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference (GlobeNewswire) +12.62%
07:01AM	Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024 (GlobeNewswire)
Oct-29-24 07:03AM	Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability (GlobeNewswire) -12.80%
07:01AM	Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants (GlobeNewswire)
Oct-16-24 07:01AM	Invivyd to Present PEMGARDA (pemivibart) Data at Infectious Disease Week (IDWeek) 2024 (GlobeNewswire)
Oct-01-24 07:01AM	Invivyd Announces U.S. FDA Has Updated the PEMGARDA EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data (GlobeNewswire) -11.75%
Sep-23-24 07:01AM	Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA (pemivibart) (GlobeNewswire)
Sep-12-24 07:01AM	Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19 (GlobeNewswire) +12.75%
Sep-05-24 07:01AM	Invivyd to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-04-24 07:01AM	Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA (GlobeNewswire)
Sep-03-24 07:01AM	Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest (GlobeNewswire)
Aug-27-24 07:01AM	Invivyd Announces PEMGARDA (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial (GlobeNewswire) -28.67%
Aug-15-24 02:43AM	Q2 2024 Invivyd Inc Earnings Call (Thomson Reuters StreetEvents) +6.12%
Aug-14-24 09:10AM	Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -7.55%
08:01AM	Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in New Haven, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ADIMAB, LLC	10% Owner	Dec 23 '25	Proposed Sale	3.00	192,320	577,498		Dec 23 04:23 PM
MCLAUGHLIN KEVIN F	Director	Nov 19 '25	Buy	2.50	50,000	125,000	50,000	Nov 20 04:22 PM
ADIMAB, LLC	10% Owner	Nov 17 '25	Proposed Sale	3.00	1,233,416	3,703,455		Nov 17 04:36 PM
Lee Timothy Edward	Chief Commercial Officer	Aug 19 '25	Sale	0.57	29,643	16,796	59,344	Aug 19 09:28 PM
Lee Timothy Edward	Chief Commercial Officer	Aug 18 '25	Sale	0.65	20,013	13,012	88,987	Aug 19 09:28 PM
Duke William E.	Chief Financial Officer	Aug 19 '25	Sale	0.57	29,643	16,796	49,344	Aug 19 09:25 PM
Duke William E.	Chief Financial Officer	Aug 18 '25	Sale	0.65	20,013	13,012	78,987	Aug 19 09:25 PM
Green Julie	Chief Human Resources Officer	Aug 19 '25	Sale	0.57	29,643	16,796	49,344	Aug 19 09:24 PM
Green Julie	Chief Human Resources Officer	Aug 18 '25	Sale	0.65	20,013	13,012	78,987	Aug 19 09:24 PM
Andersen Jill	Chief Legal Officer, Secretary	Aug 19 '25	Sale	0.57	49,402	27,991	84,446	Aug 19 09:21 PM
Andersen Jill	Chief Legal Officer, Secretary	Aug 18 '25	Sale	0.65	33,352	21,685	133,848	Aug 19 09:21 PM
Allen Robert D. III	Chief Scientific Officer	Aug 19 '25	Sale	0.57	27,420	15,536	53,068	Aug 19 09:20 PM
Allen Robert D. III	Chief Scientific Officer	Aug 18 '25	Sale	0.65	18,512	12,037	80,488	Aug 19 09:20 PM
Green Julie	Officer	Aug 18 '25	Proposed Sale	0.71	39,600	28,001		Aug 18 06:55 PM
Andersen Jill	Officer	Aug 18 '25	Proposed Sale	0.71	66,000	46,669		Aug 18 06:54 PM
Allen Robert D. III	Officer	Aug 18 '25	Proposed Sale	0.71	36,631	25,902		Aug 18 06:53 PM
Lee Timothy Edward	Officer	Aug 18 '25	Proposed Sale	0.71	39,600	28,001		Aug 18 06:49 PM
Duke William E.	Officer	Aug 18 '25	Proposed Sale	0.71	39,601	28,002		Aug 18 06:44 PM

TECX

Tectonic Therapeutic Inc

IVVD

Invivyd Inc

Upgrade your FINVIZ experience